Following promising Results from a pilot phase II trial of temozolomide plus radiotherapy ... were newly diagnosed glioblastoma (WHO GRADE IV ASTROCYTOMA), a performance status of ≤2, and ...

The Phase III STELLAR trial evaluated the eflornithine and lomustine combination in patients with IDH mutant astrocytoma.

The median survival for patients with glioblastoma multiforme (GBM), the most common and malignant form (WHO grade 4), is only 12–15 months, whereas that of anaplastic gliomas (WHO grade 3 ...

Temozolomide with radiation therapy is the 'standard' for adult and pediatric malignant gliomas but not for pediatric diffuse intrinsic pontine gliomas.